was performed. Breast cancer prevalence was determined based on the number of females (21-64 years) having at least one medical services claim with a primary diagnosis of breast cancer 233.0x, 238.3x, or 239.3x) (ICD9 189.0 or 198.0), continuous health care coverage, 180 days' coverage before RCC diagnosis, and no claim for sorafenib or sunitinib before RCC diagnosis, who received a standard RCC initial daily dosage of sorafenib 800 mg or sunitinib 50 mg and 2 consecutive dispensings, were included. Initial episode was defi ned as time from date of fi rst drug-dispensing to fi rst of switch to another TKI, health care coverage end, treatment end, or March 31, 2008. Both patient and patient-time level analyses for dose reductions between treatments were conducted. RESULTS: Baseline demographics between the groups (sorafenib, n 189; sunitinib, n 304) were similar except for a higher incidence of stroke (7.9% vs. 3.6%, P .037) and other cancer site (93.7% vs. 87.8%, P 0.036) in the sorafenib group. Signifi cantly more patients receiving sunitinib required dose reductions compared with sorafenib (fi rst 3 months: 23.0% vs 4.2%; complete initial episodes: 35.5% vs 16.9%; P 0.001 for both). For all episodes, mean time to dose reduction was signifi cantly longer for sorafenib than sunitinib (162 days vs 104 days, P 0.003). Signifi cantly more dose reductions occurred within the fi rst 3 months with sunitinib than sorafenib (65% vs. 25%, P 0.001). Controlling for different lengths of exposure time further confi rmed that more dose reductions were observed in patients treated with sunitinib than with sorafenib (from 2-6 times greater, P 0.001). CONCLUSIONS: This retrospective US claims analysis showed that signifi cantly more dose reductions, including total number of patients and days, were required in patients who initially received sunitinib than in those who received sorafenib. (ICD9 189.0 or 198.0), continuous health care coverage, and 180 days coverage before diagnosis were included. Patients were followed from diagnosis until health care coverage end or June 30, 2008. Conditions, symptoms, and individual Charlson comorbidities were assessed. Treatment was analyzed using prevalence and time to initiation in patients and 65 years old. RESULTS: Of 12,253 patients identifi ed, 61.8% were male (mean age, 63 years old) and 51.0% were 65 years old. Overall, pain (59.6%), hypertension (53.7%), anemia (23.2%), diabetes (23.6%), and chronic kidney disease (19.4%) were most common comorbidities reported. Most comorbidities were prevalent in 65 years old than 65 years old: notably, cerebrovascular disease (8.7% vs. 3%; P 0.001), acute myocardial infarction (2% vs 0.7%; P 0.001), and chronic renal failure (9.3% vs. 6%; P 0.001). In 65 and 65 groups, most commonly used treatments were nephrectomy (53.4% vs. 40.4%; P .001), intravenous chemotherapy (11.7% vs. 13.3%; P 0.0079) and oral chemotherapy (10.5% vs. 13.3%; P 0.0001), although less than 4% of patients in either group received FDA-approved oral agents sorafenib or sunitinib. For 65 and 65 groups, respectively, mean time from RCC diagnosis to: nephrectomy, 25 and 31 days; radiotherapy, 170 and 177 days; intravenous chemotherapy, 154 and 181 days; sorafenib, 220 and 247 days; sunitinib, 221 and 205 days. CONCLUSIONS: Baseline comorbidities and symptoms were more common in RCC patients 65 years old than those 65 years old. Nephrectomy was used more frequently in patients 65, probably because of comorbidities in older patients. In contrast, systemic treatment was similar in both groups. The objective of this study was to examine the utilization patterns of cancer medications beyond their labeled indications approved by the FDA in community oncology practices. METHODS: Drug prescription information from a community oncology data warehouse was used for two separate analyses. Patients were categorized according to whether they had an ICD-9 diagnosis code for one of four cancer types including lung, breast, bladder or gastric, and having no other malignancy. The frequency of use of various oncology drugs was examined for each of these groups, against a set of medications that were FDA-approved for these indications or were recommended by NCCN guidelines. In the second analysis, patients with a single malignancy, who received any of the fi ve oncology drugs (paclitaxel, vinorelbine, rituximab, bevacizumab) and gemcitabine, were counted. Comparisons were then made against the cancer indications for which these agents were approved by the FDA. RESULTS: Seventy-eight percent of breast and 95% of lung cancer patients received medications approved for these indications, while 68% and 75% also received drugs that were not approved by the FDA for those conditions. More than 99.7% of these patients received agents recommended on NCCN guidelines. None of the bladder cancer patients and only 5% of gastric cancer patients received drugs approved for these indications, while 97% and 95% of them received guideline-recommended drugs. Only half of the patients given paclitaxel or bevacizumab received these for an FDA-approved indication. In the case of vinorelbine and gemictabine, the proportion was lower at 30% and 40% respectively, while it was higher for rituximab at 60%. CONCLUSIONS: Oncologists' choice of drugs is driven by evidence-based guidelines, independent of FDA approval. There is a high and varying proportion of off-label use across oncology medications and cancer types.
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GASTROINTESTINAL DISORDERS -Clinical Outcomes Studies
PGI1 A SYSTEMATIC REVIEW ON KUSHENIN VERSUS WESTERN MEDICINES FOR PATIENTS WITH CHRONIC HEPATITIS B
Bian B 1 , Shao R 2 , Xia Y 2 , Guo JJ 3 , Chen Y 2 1 University of Cincinnati, Cincinnanti, OH, USA, 2 China Pharmaceutical University, Nanjing, Jiangsu, China, 3 University of Cincinnati, Cincinnati, OH, USA OBJECTIVES: Hepatitis B virus infected over 2 billion people worldwide, and 350 million suffering from chronic HBV infection. The prevalence of chronic HBV infection is high in Asia and most of Africa. Kushenin injection as a new traditional Chinese medicine is now widely used for chronic HBV treatment in China. The objective of this study was to compare the effectiveness between Kushenin and western medicines on patients with chronic HBV. METHODS: Based on a pilot study of patient interview at one hospital setting, we identifi ed key outcome measurements of effectiveness related to Kushenin and western medicine, including ALT recovery rate and negative conversion rate of HBeAg. Consequently, we performed a systematic literature review using computer-based search-engines such as MEDLINE (1966 to 2007 ), EMBASE (1966 to 2006 , OVID (1965 OVID ( to 2006 , the Chinese Biomedical Database (CBM) (1978 to 2006) and CNKI (China National Knowledge Infrastructure) (1994 to 2007) . From available data, both interferon and lamivudine were selected as western medicines to compare with Kushenin regimen. A Meta-analysis was performed using a software program of Reviewmanager 4.2. RESULTS: A total of 15 published clinical studies involving 1396 patients met inclusion criteria for the meta-analysis. Comparing to interferon alone regimen, Kushenin showed no signifi cant differences in terms of ALT recovery rate [relative risk, RR 0.96; 95% confi dence interval (CIs),0.86-1.09] and negative conversion rate of HBeAg (RR 0.85; 95%CIs, 0.69-1.05). Meanwhile, kushenin combined with lamivudine showed better effectiveness in term of ALT recovery rate (RR 1.77; 95%CIs,1.38-2.26) and negative conversion rate of HBeAg (RR 2.58; 95% CIs, 1.81-3.68) compared with lamivudine alone. CONCLUSIONS: Integrated Kushenin plus lamivudine showed better clinical outcomes in ALT recovery rate and HBeAg negative conversion rate. Further evidence-based analysis is required due to low quality of randomization procedure in clinical trials and insuffi cient study patients for treating chronic HBV with kunshenin.
